Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Sales and Divestitures (2016 - 2022)

Historic Gains from Sales and Divestitures for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Q1 2022 value amounting to $931063.0.

  • Arrowhead Pharmaceuticals' Gains from Sales and Divestitures rose 1305.14% to $931063.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $931063.0, marking a year-over-year increase of 1305.14%. This contributed to the annual value of $899025.0 for FY2021, which is 2242.45% down from last year.
  • As of Q1 2022, Arrowhead Pharmaceuticals' Gains from Sales and Divestitures stood at $931063.0, which was up 1305.14% from $263700.0 recorded in Q4 2021.
  • In the past 5 years, Arrowhead Pharmaceuticals' Gains from Sales and Divestitures registered a high of $2.2 million during Q1 2019, and its lowest value of $263700.0 during Q4 2021.
  • Its 5-year average for Gains from Sales and Divestitures is $1.1 million, with a median of $955404.0 in 2020.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first skyrocketed by 648959.0% in 2018, then crashed by 5651.93% in 2020.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Gains from Sales and Divestitures stood at $658959.0 in 2018, then decreased by 19.06% to $533333.0 in 2019, then plummeted by 47.44% to $280325.0 in 2020, then dropped by 5.93% to $263700.0 in 2021, then surged by 253.08% to $931063.0 in 2022.
  • Its Gains from Sales and Divestitures was $931063.0 in Q1 2022, compared to $263700.0 in Q4 2021 and $899025.0 in Q3 2021.